Aktie A3DM8E INNOVEREN SCIENTIFIC INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Innoveren Scientific Inc.

Aktien

A3DM8E

US4041243076

IVRN

Markt geschlossen - OTC Markets
Andere Börsenplätze
 17:46:52 17.04.2024 		% 5 Tage % 1. Jan.
0.02 USD -33.33% Intraday Chart für Innoveren Scientific Inc. 0.00% -82.76%
06.03. Innoveren Scientific kündigt 510(K)-Einreichung bei der U.S. Federal Food and Drug Administration für Skindisc(Tm) Lite an CI
2023 Innoveren Scientific Inc. meldet Ergebnis für das dritte Quartal und die neun Monate bis zum 30. September 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Innoveren Scientific Announces 510(K) Submission to U.S. Federal Food and Drug Administration for Skindisc(Tm) Lite
Innoveren Scientific Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Innoveren Scientific Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
H-Cyte, Inc. has Changed its Name to Innoveren Scientific Inc
Innoveren Scientific Inc. has Changed its Ticker to IVRN from HCYT
H-CYTE, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
H-CYTE, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
H-CYTE, Inc. Auditor Raises 'Going Concern' Doubt
H-CYTE, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
H-CYTE, Inc. announced that it expects to receive $0.135 million in funding
H-CYTE, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
H-CYTE, Inc. announced that it expects to receive $0.3 million in funding
H-CYTE Completes Acquisition of SkinDisc™ Regenerative Tissue Kit from Scion Solutions, LLC
H-CYTE, Inc. (OTCQB: HCYT) completed the acquisition of SkinDisc from Tanya Rhodes, Brock Liden, Spencer T Brown and Spencer T Brown.
H-CYTE, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
H-CYTE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
H-CYTE, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
H-CYTE, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
H-CYTE, Inc. announced that it has received $0.225 million in funding
H-CYTE Announces Intent to Acquire SkinDisc, Expects to Complete Within 30 Days
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3DM8E Aktie
  4. Nachrichten Innoveren Scientific Inc.
  5. Andere Sprachen